Opko Health, Inc.

Good day and welcome to the Opco Health Fourth Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Yvonne Briggs with LHA. Please go ahead.

Thank you, Operator, and good afternoon. This is Yvonne Briggs with LHA. Thank you all for joining today's call to discuss Opco Health financial results for the fourth quarter of 2022. I'd like to remind you that any statements made during this call by management other than statements of historical fact will be considered forward-looking, and as such, will be subject to risks and uncertainties that can materially affect the company's expected results. Those forward-looking statements include, without limitation, the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2022, and in subsequently filed SEC reports. Conference call contains time-sensitive information that is accurate only as of the date of the live broadcast today, February 23, 2023. Except as required by law, OPCO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Before we begin, let me review the format for today's call. Dr. Philip Frost, Chairman and Chief Executive Officer, will open the call. Dr. Elias Sirhouni, Vice Chairman and President of Opco, will then provide an overview of Opco's pharmaceutical business as well as bioreference laboratories. After that, Adam Logel, Opco's CFO, will review the company's fourth quarter financial results and then will open the call to questions. Now I'd like to turn the call over to Dr. Frost.

are underway by our commercial partner, Pfizer, and generally is our once-weekly injectable growth hormone product developed to ease a patient's burden versus the standard daily injections. Pfizer has launched the product in 15 countries, including Japan, Germany, and the U.K., and expects to have launched in all priority markets by the end of the year. As I mentioned on our last call, Ingenila is starting to post significant sequential quarterly sales growth, and Adam will review Opco's profit share and royalty payments in his prepared remarks. We believe Pfizer is making progress in the U.S. to advance Ingenila through the regulatory process and address the FDA's comments. We continue to work with Pfizer as they stand by their commitment to commercialize Ingenila globally and will provide further updates on its regulatory status in the U.S. and commercial progress in foreign countries. As for our clinical diagnostics business, BioReference Laboratories is making significant progress in reducing costs and right-sizing the business. In parallel, BRL is expanding its portfolio by focusing on innovation in its specialty testing segments, including oncology, women's health, and urology. while driving growth with novel partnership arrangements. Elias will provide further details on the lab and its performance following his commentary on the pharmaceutical business. With that brief overview, I'll now turn the call over to Elias. Elias?